To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2012 News Releases

About RSS

Global News

AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-FreeSurvival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial (pdf 66KB)

January 4, 2012

Printer-friendly version

Main Text end
Local Navigation
Local Navigation end
Related Links